The group ENHYPEN, boosted by the support of its fans, has added an extra show to its Singapore concert as part of its world tour.
On August 12, the agency Belift Lab announced on the fan platform Weverse: “Thanks to the support of our ENGENE (the fandom name), an additional show of ENHYPEN WORLD TOUR ‘WALK THE LINE’ IN SINGAPORE (hereafter WALK THE LINE) has been added.”
Originally scheduled for October 4 and 5, the Singapore concerts quickly sold out after ticket sales opened, so the group decided to add another show to connect with more local fans. ENHYPEN will now perform for three days, from October 3 to 5, at the Singapore Indoor Stadium.
The world tour “WALK THE LINE,” which began last October at the main stadium of the Goyang Sports Complex, includes a total of 32 shows across 19 cities worldwide. The group performs in large venues such as domes and stadiums, confirming its growing popularity.
“WALK THE LINE” has helped ENHYPEN break several records. Between November 2023 and January 2024, they were the fastest K-pop boy band to hold a dome tour across three domes (Saitama Super Arena, Fukuoka PayPay Dome, and Kyocera Dome Osaka). In July and August, they became the fastest foreign artists (in 4 years and 7 months) to perform at Japanese stadiums (Tokyo Ajinomoto Stadium and Osaka Yanmar Stadium).
ENGENE’s response in cities on the “WALK THE LINE” tour has been especially enthusiastic. Not only in Singapore, but also in most US and European stops, Chicago, Los Angeles, London, Amsterdam, Brussels, Berlin, Paris, the tickets sold out very quickly. Last June, Thailand’s largest venue, Rajamangala National Stadium, was also sold out.
ENHYPEN kicked off the IN U.S. & EUROPE leg of its “WALK THE LINE” tour on August 6 and 7 (local time) at UBS Arena in Belmont Park, New York. They then performed on August 9 at Chicago’s United Center, followed by August 12 and 13 at Houston’s Toyota Center. On August 16, they will take the stage at Los Angeles’ BMO Stadium.
Journalist: Shawn
Translator: Shawn
Source: SNS ENHYPEN
